Study determines costs of breast and cervical cancer detection among low-income women

December 21, 2007

A new study has estimated the costs of providing comprehensive screening and diagnostic services to under-or uninsured, low-income women to identify those with breast or cervical cancer for treatment. Dr. Donatus U. Ekwueme of the National Center for Chronic Disease Prevention and Health Promotion at the Centers for Disease Control and Prevention in Atlanta and colleagues found that the median cost of screening a woman for breast cancer was $94, and the cost per breast cancer detected was $10,566. For cervical cancer, these costs were $56 and $13,340, respectively. The study is published in the February 1, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.

Many deaths from breast and cervical cancer would be avoidable through the use of mammography and Pap tests, respectively. In 1990 Congress established the National Breast and Cervical Cancer Early Detection Program (NBCCEDP)--which is now the largest cancer screening program in the United States--to provide support and assistance to increase breast and cervical cancer screening among medically under-served, low-income women. Program services are available in all 50 states, the District of Columbia (DC), 4 U.S. territories, and 13 American Indian/Alaskan Native organizations. To help determine the level of funding required to reach and screen eligible women, Ekwueme and colleagues set out to estimate the costs per woman served, per woman screened and per cancer detected through this program.

The investigators collected data from July 2003 through June 2004 from nine of the 68 NBCCEDP programs operating in the United States. They found that when non-federal contributions are included, the median cost of all screening services combined was $555 per woman. Screening tests accounted for the highest cost, $221 per woman served, and public education/outreach incurred the second highest cost, $63.

The analysis revealed that 58.2 percent of the program's resources were allocated to clinical services, including screening and diagnostic follow-up, referral for treatment, and case management. The remainder of NBCCEDP's funds were used to support non-screening activities such as data management, public education/outreach, professional education and quality assurance and improvement.

The authors note that the study "provides the first systematic cost analysis in the selected [NBCCEDP] programs and is unique in that it attempts to determine the real costs of providing comprehensive screening and diagnostic follow-up services to low-income, uninsured women." The Centers for Disease Control and Prevention is currently assessing the long-term economic issues in all of the programs within NBCCEDP. These analyses "will provide invaluable information that program directors and managers can use to make informed decisions on how to allocate NBCCEDP resources more efficiently," the authors conclude.
-end-
Article: "Cost Analysis of the National Breast and Cervical Cancer Early Detection Program--Selected States, 2003-2004." Donatus U. Ekwueme, James G. Gardner, Sujha Subramanian, Florence K. Tangka, Bela Bapat, and Lisa C. Richardson. CANCER; Published Online: December 21, 2007 (DOI: 10.1002/cncr.23207); Print Issue Date: February 1, 2008.

Contact: Office of Communications, National Center for Chronic Disease Prevention and Health Promotion Centers for Disease Control and Prevention, 770-488-5131, Aob4@cdc.gov

Wiley

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.